Patient reported outcomes in patients with head and neck cancer treated with concurrent chemoradiation with weekly versus bolus cisplatin. Issue 12 (19th August 2020)

• Record Type: Journal Article
• Authors: Arbab, Mona; Chen, Yu‐Hui; Criscitiello, Shana; Glass, Jason; Fugazzotto, Jo Ann; Killoran, Joseph H.; Hanna, Glenn; Lorch, Jochen; Haddad, Robert I.; Margalit, Danielle N.; Tishler, Roy B.; Schoenfeld, Jonathan D.
• Is Part Of: Head & neck. Volume 42:Issue 12(2020)
• Page Start: 3670
• Page End: 3677
• Publication Date: 2020-08-19
• Subjects: bolus cisplatin -- chemoradiation -- head and neck cancer -- patient reported outcome -- weekly cisplatin; Head -- Diseases -- Periodicals; Neck -- Diseases -- Periodicals; Head -- Periodicals; Neck -- Periodicals; Face -- Periodicals; 617.51059
• DOI: 10.1002/hed.26432
• Languages: English
• ISSNs: 1043-3074

Abstract

Abstract: Background: Patient Reported Outcome (PRO) data comparing bolus (B‐CP) with weekly (W‐CP) cisplatin concurrent with radiation are lacking. Methods: We performed a retrospective study comparing PRO among 99 patients with head and neck radiation, 26% who received concurrent B‐CP and 73% treated with W‐CP. Results: W‐CP patients had a higher Charlson comorbidity index (CCI) ( P = .004). There were no differences in median cisplatin dose, PROs, percutaneous endoscopic gastrostomy (PEG) dependence or hospitalization between arms. Patients with a greater decline in their self‐reported dysphagia score were more often PEG dependent at the end of radiation therapy ( P = .03). There was also a trend toward PEG dependence with a higher maximum dysphagia score and greater change in aspiration score ( P = .06). The maximum decline in white cell count and absolute neutrophil count were greater in the W‐CP group ( P = .04, P = .01). Conclusion: Both B‐CP and W‐CP are well tolerated. PROs do not suggest a benefit to W‐CP.